TITLE

Prolonged antithrombotic pretreatment increased risk for MI or death in unstable coronary syndromes

PUB. DATE
March 2004
SOURCE
ACP Journal Club;Mar/Apr2004, Vol. 140 Issue 2, p30
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article analyses if prolonged antithrombotic pretreatment for 3 to 5 days is more effective than early intervention and pretreatment for≤ 6 hours before cardiac catheterization in patients with unstable coronary syndromes. An analysis was performed with an intention to treat. The composite endpoint was reached by more patients in the prolonged pretreatment group than the early intervention group. Groups did not differ for major bleeding events. It was concluded that prolonged antithrombotic pretreatment before cardiac catheterization increased the risk for large myocardial infarction or death at 30 days.
ACCESSION #
12597110

 

Related Articles

  • Impact of on-site cardiac catheterization on resource utilization and fatal and non-fatal outcomes after acute myocardial infarction. Halabi, Abdul R.; Beck, Christine A.; Eisenberg, Mark J.; Richard, Hugues; Pilote, Louise // BMC Health Services Research;2006, Vol. 6, p148 

    Background: Patterns of care for acute myocardial infarction (AMI) strongly depend on the availability of on-site cardiac catheterization facilities. Although the management found at hospitals without on-site catheterization does not lead to increased mortality, little it known about its impact...

  • MYOCARDIAL ISCHEMIA CAUSED BY CORONARY-PULMONARY FISTULA AND CORONARY ATHEROSCLEROSIS. Reza, G.; Farsad, H. // Vascular Surgery;Sep/Oct1978, Vol. 12 Issue 5, p324 

    A 57-year-old woman suffered from atypical angina after a myocardial infarction. Coronary artery occlusive disease and fistula between the coronary artery and pulmonary artery was identified by cardiac catheterization. The result of medical treatment was borderline, and she did not respond to...

  • Adjunctive Use of Direct Thrombin Inhibitors in Patients Receiving Fibrinolytic Therapy for Acute Myocardial Infarction. John K. French; John J. Edmond; Wanzhen Gao; Harvey D. White; John W. Eikelboom // American Journal of Cardiovascular Drugs;2004, Vol. 4 Issue 2, p107 

    The direct thrombin inhibitors hirudin and bivalirudin inhibit both fluid-phase and clot-bound thrombin. These agents have been extensively studied in clinical trials in comparison with intravenous unfractionated heparin (UFH), as adjuncts to fibrinolytic therapy for ST-elevation myocardial...

  • Antithrombotic Therapy. Duvall, W. L. // Current Molecular Medicine;Aug2006, Vol. 6 Issue 5, p603 

    Coronary heart disease is the leading cause of death in the US and the industrialized world. Ever since DeWood in 1980 demonstrated that a thrombus was the primary event leading to acute myocardial infarction and that they may subsequently lyse, the mainstay of therapy for the past 25 years has...

  • Management of ST-Elevation Myocardial Infarction: An Update on Pharmacoinvasive Recanalization. Kashani, Amir; Giugliano, Robert P. // American Journal of Cardiovascular Drugs;2008, Vol. 8 Issue 3, p187 

    The immediate goal of reperfusion in acute ST-elevation myocardial infarction (STEMI) is the prompt restoration of myocardial blood flow. Over the past 50 years, numerous advances have been made in achieving this goal by combining pharmacologic regimens with primary percutaneous coronary...

  • Invasive strategy underused in ACS.  // Heart;Jun2008, Vol. 94 Issue 6, p818 

    The article presents a study on the application of invasive strategy in the treament of patients with acute coronary syndromes (ACS). The study investigated the selection of patients for cardiac catheterisation and used the Thrombolysis in Myocardial Infarction (TIMI) risk score. Results showed...

  • Precocious virulent coronary atherosclerosis in the very young. Chait, Robert; Ramineni, Rajesh; Fender, Erin A. // Cardiology in the Young;Apr2012, Vol. 22 Issue 2, p184 

    BackgroundThe incidence of Myocardial Infarction (MI) in patients under the age of 30 has been rarely addressed. Moreover, it is not understood why these patients develop symptomatic Coronary Artery Disease (CAD) at such an early age. Traditional risk factor assessment has not been successful in...

  • Thrombolysis in the Treatment of Acute Transmural Myocardial Infarction. Smith, Budge; Kennedy, J. Ward // Annals of Internal Medicine;Mar87, Vol. 106 Issue 3, p414 

    Examines the use of thrombolytic agents in a therapeutic program of patient management in acute myocardial infarction. Prevalence of intracoronary thrombi at autopsy; Intracoronary streptokinase as a method of reperfusion of ischemic myocardium; Infusion complications with thrombolytic therapy.

  • Fibrinolytic therapy and bleeding complications: risk predictors from RIKS-HIA. Oldgren, Jonas; Wernroth, Lisa; Stenestrand, Ulf // Heart;Sep2010, Vol. 96 Issue 18, p1451 

    Background Fibrinolytic treatment for ST-elevation myocardial infarction is associated with increased bleeding risk but is still widely used world wide, mainly because of limited access to primary PCI. Objective To analyse contemporary fibrinolytic treatment patterns, in-hospital bleeding risk...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics